GENB Stock Analysis: Generate Biomedicines | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 2.232m USD | 12M Return: 25.6% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 14.2M
Warnings
Tailwinds
No distinct edge detected
Seasonality 0.3 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Generate Biomedicines, Inc. (NASDAQ: GENB) is a clinical-stage biotechnology company that applies machine learning and generative biology to engineer novel protein therapeutics for drug discovery and development. The company was incorporated in 2018 in Somerville, Massachusetts, originally as Generate Biologics, Inc., before adopting its current name in February 2020. It went public on NASDAQ on February 27, 2026.
The companys pipeline spans multiple protein-based modalities, including GB-0895, an investigational long-acting anti-TSLP monoclonal antibody in development for severe asthma designed for twice-yearly dosing; GB-4362, a monoclonal antibody targeting MMAE payload neutralization; and GB-5267, a MUC16-directed CAR-T cell therapy. These programs reflect a strategy that combines antibody engineering with cell therapy approaches, two of the more active segments within the broader biotech industry.
Underpinning these programs is the Generate Platform, a therapeutic-area and modality-agnostic system that integrates computational design with scalable biohardware. The platform reflects the wider industry shift toward AI-driven drug discovery, where machine learning models are used to design protein sequences with target properties, aiming to expand the addressable range of treatable diseases beyond what traditional empirical screening methods can reach.
- GB-0895 severe asthma Phase 1 data readout ahead
- Cash burn accelerates as multiple programs enter clinic
- AI drug discovery competition intensifies from biotech rivals
| Net Income: -203.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.33 > 0.02 and ΔFCF/TA -9.24 > 1.0 |
| NWC/Revenue: 1.50k% < 20% (prev 1.57k%; Δ -72.70% < -1%) |
| CFO/TA -0.32 > 3% & CFO -200.6m > Net Income -203.2m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 9.17 > 1.5 & < 3 |
| Outstanding Shares: last fiscal year (50.1m) vs prev -60.70% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 5.58% > 50% (prev 3.95%; Δ 1.63% > 0%) |
| Interest Coverage Ratio: -195.1 > 6 (EBIT TTM -221.7m / Interest Expense TTM 1.14m) |
| A: 0.76 (Total Current Assets 535.4m - Total Current Liabilities 58.4m) / Total Assets 625.7m |
| B: -1.18 (Retained Earnings -737.7m / Total Assets 625.7m) |
| C: -0.39 (EBIT TTM -221.7m / Avg Total Assets 572.0m) |
| D: 4.64 (Book Value of Equity 514.8m / Total Liabilities 110.9m) |
| Altman-Z'' = 3.43 = A |
As of July 08, 2026, the stock is trading at USD 16.22 with a total of 920,155 shares traded. Over the past week, the price has changed by -4.08%, over one month by +26.92%, over three months by +37.11% and over the past year by +25.64%.
Current recommended Stop Loss: 14.30 (which is 11.8% or 1.6 ATR below the current price).
Generate Biomedicines has no consensus analysts rating.
P/S = 73.6602
P/B = 4.3353
Revenue TTM = 31.9m USD
EBIT TTM = -221.7m USD
EBITDA TTM = -208.5m USD
Long Term Debt = 51.3m USD (estimated: total debt 65.6m - short term 14.3m)
Short Term Debt = 14.3m USD (from shortTermDebt, last quarter)
Debt = 65.6m USD (from shortLongTermDebtTotal, last quarter) (leases 65.6m already included)
Net Debt = -451.1m USD (calculated: Debt 65.6m - CCE 516.6m)
Enterprise Value = 1.78b USD (2.23b + Debt 65.6m - CCE 516.6m)
Interest Coverage Ratio = -195.1 (Ebit TTM -221.7m / Interest Expense TTM 1.14m)
EV/FCF = -8.72x (Enterprise Value 1.78b / FCF TTM -204.1m)
FCF Yield = -11.46% (FCF TTM -204.1m / Enterprise Value 1.78b)
FCF Margin = -640.1% (FCF TTM -204.1m / Revenue TTM 31.9m)
Net Margin = -637.0% (Net Income TTM -203.2m / Revenue TTM 31.9m)
Gross Margin = unknown ((Revenue TTM 31.9m - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = 2.85 (Enterprise Value 1.78b / Total Assets 625.7m)
Interest Expense / Debt = 1.73% (Interest Expense 1.14m / Debt 65.6m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -175.1m (EBIT -221.7m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 9.17 (Total Current Assets 535.4m / Total Current Liabilities 58.4m)
Debt / Equity = 0.13 (Debt 65.6m / totalStockholderEquity, last quarter 514.8m)
Debt / EBITDA = 2.16 (negative EBITDA) (Net Debt -451.1m / EBITDA -208.5m)
Debt / FCF = 2.21 (negative FCF - burning cash) (Net Debt -451.1m / FCF TTM -204.1m)
Total Stockholder Equity = -616.0m (last fiscal year from totalStockholderEquity)
RoA = -35.52% (Net Income -203.2m / Total Assets 625.7m)
RoE = 32.98% (negative equity) (Net Income TTM -203.2m / Total Stockholder Equity -616.0m)
RoCE = 39.26% (negative capital employed) (EBIT -221.7m / Capital Employed (Equity -616.0m + L.T.Debt 51.3m))
RoIC = -30.19% (negative operating profit) (NOPAT -175.1m / Invested Capital 580.0m)
WACC = 8.29% (E(2.23b)/V(2.30b) * Re(8.49%) + D(65.6m)/V(2.30b) * Rd(1.73%) * (1-Tc(0.21)))
Discount Rate = 8.49% (= CAPM, Blume Beta Adj.)
[DCF] Fair Price = unknown (Cash Flow -204.1m)
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: N/A | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.49 | Chg30d=-11.93% | Revisions=-40% | Analysts=4
EPS next Quarter (2026-09-30): EPS=-0.54 | Chg30d=-16.56% | Revisions=-50% | Analysts=4
EPS current Year (2026-12-31): EPS=-2.24 | Chg30d=-18.31% | Revisions=-50% | GrowthEPS=+0.0% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-2.06 | Chg30d=+2.59% | Revisions=+17% | GrowthEPS=+7.8% | GrowthRev=-8.6%
[Analyst] Revisions Ratio: -50% (up=2, down=9)